Your browser doesn't support javascript.
loading
Economic Costs of Cardiovascular Diseases in Poland Estimates for 2015-2017 Years.
Mela, Aneta; Rdzanek, Elzbieta; Poniatowski, Lukasz A; Jaroszynski, Janusz; Furtak-Niczyporuk, Marzena; Galazka-Sobotka, Malgorzata; Olejniczak, Dominik; Niewada, Maciej; Staniszewska, Anna.
Afiliación
  • Mela A; Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT), Medical University of Warsaw, Warsaw, Poland.
  • Rdzanek E; Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT), Medical University of Warsaw, Warsaw, Poland.
  • Poniatowski LA; Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT), Medical University of Warsaw, Warsaw, Poland.
  • Jaroszynski J; Department of Neurosurgery, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
  • Furtak-Niczyporuk M; Chair of Administrative Procedure, Faculty of Law and Administration, Maria Curie-Sklodowska University of Lublin, Lublin, Poland.
  • Galazka-Sobotka M; Department of Public Health, Faculty of Medicine, Medical University of Lublin, Lublin, Poland.
  • Olejniczak D; Department of Management and Marketing, Faculty of Economics and Management, Lazarski University, Warsaw, Poland.
  • Niewada M; Institute of Management in Health Care, Lazarski University, Warsaw, Poland.
  • Staniszewska A; Department of Public Health, Faculty of Health Sciences, Medical University of Warsaw, Warsaw, Poland.
Front Pharmacol ; 11: 1231, 2020.
Article en En | MEDLINE | ID: mdl-33013357
BACKGROUND: Cardiovascular diseases are associated with growing public and private expenditure on healthcare regardless geographic region. Therefore, it is necessary to accurately estimate the overall societal costs-both direct and indirect expenses from the perspective of patients, caregivers and employers. RESEARCH DESIGN: The aim of this paper is to determine the direct and indirect costs related to cardiovascular diseases in Poland from 2015 to 2017. All costs are estimated based on data available in the public domain and obtained from the major Polish institutions. Indirect costs were calculated using a modified human capital approach. RESULTS: The financial burden of cardiovascular diseases in Poland is significant. This study revealed that total costs (direct and indirect) of cardiovascular diseases, for 2015-2017, range from 34.9 bn PLN (8.2 bn EUR) to over 40.9 bn PLN (9.6 bn EUR). Total direct cost and indirect costs were approximately 6.1 bn PLN (1.4 bn EUR) (16%) and 31.3 bn PLN (7.3 bn EUR) (84%), respectively. CONCLUSION: Collectively, the estimated direct and indirect cost of cardiovascular diseases provide a useful input for economic impact assessments of public health programs and health technology analyses.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Health_economic_evaluation Idioma: En Revista: Front Pharmacol Año: 2020 Tipo del documento: Article País de afiliación: Polonia Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Health_economic_evaluation Idioma: En Revista: Front Pharmacol Año: 2020 Tipo del documento: Article País de afiliación: Polonia Pais de publicación: Suiza